Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma

Table 1 In vitro clonogenicity - mean surviving fractions (SEM) after treatment with ionizing radiation (IR, 5 Gy), vorinostat and hypoxia

	HCT116		HT29		SW620		KM20L2
	SF	p	SF	p	SF	p	SF	p
Monotherapy (relative to control)
IR	0.029 (0.04)	<0.001	0.33 (0.02)	<0.001	0.079 (0.02)	<0.001	0.11 (0.002)	<0.001
HO	0.97 (0.08)	0.7	0.98 (0.03)	0.6	0.62 (0.28)	0.3	0.92 (0.01)	0.01
VOR	0.35 (0.04)	<0.001	0.78 (0.07)	0.05	0.84 (0.04)	0.07	0.66 (0.04)	0.04
Combination therapy
IR-HO (relative to HO)	0.13 (0.03)	<0.001	0.51 (0.05)	0.002	0.36 (0.10)	0.02	0.20 (0.02)	<0.001
VOR-HO (relative to HO)	0.41 (0.05)	<0.001	0.88 (0.09)	0.3	0.68 (0.14)	0.1	0.68 (0.03)	0.08
VOR-IR (relative to VOR)	0.011 (0.004)	<0.001	0.18 (0.03)	<0.001	0.026 (0.02)	<0.001	0.066 (0.02)	<0.001
VOR-IR-HO (relative to VOR-HO)	0.020 (0.005)	<0.001	0.24 (0.02)	<0.001	0.052 (0.03)	<0.001	0.040 (0.006)	<0.001

SF = surviving fractions; HO = hypoxia; VOR = vorinostat; IR-HO = IR under hypoxia;
VOR-HO = vorinostat under hypoxia; VOR-IR = vorinostat and IR; VOR-IR-HO = vorinostat and IR under hypoxia.

ISSN: 1748-717X